Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2010 Oct 15;20(20):6096-9. doi: 10.1016/j.bmcl.2010.08.045. Epub 2010 Aug 14.

4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors.

Author information

1
Pfizer Global Research and Development, Chemistry Department, La Jolla, CA 92120, USA. kevin.k.liu@pfizer.com

Abstract

Pteridinones were designed based on a non-selective kinase template. Because of the uniqueness of the PI3K and mTOR binding pockets, a methyl group was introduced to C-4 position of the peteridinone core to give compounds with excellent selectivity for PI3K and mTOR. This series of compounds were further optimized to improve their potency against PI3Kα and mTOR. Finally, orally active compounds with improved solubility and robust in vivo efficacy in tumor growth inhibition were identified as well.

PMID:
20817449
DOI:
10.1016/j.bmcl.2010.08.045
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center